Piśmiennictwo

1. Craske MG, Rauch SL, Ursano R, Prenoveau J, Pine DS, Zinbarg RE. What is an anxiety disorder? Depress Anxiety 2009;26(12):1066-85

2. Rickels K, Rynn M. Overview and clinical presentation of generalized anxiety disorder. Psychiatr Clin North Am 2001;24(1):1-17

3. Andreescu C, Tudorascu D, Sheu LK, Rangarajan A, Butters MA, Walker S et al. Brain structural changes in late-life generalized anxiety disorder. Psychiatry Res Neuroimaging [Internet] 2017 Oct;268:15-21

4. Kazeminia M, Salari N, Vaisi-Raygani A, Jalali R, Abdi A, Mohammadi M et al. The effect of exercise on anxiety in the elderly worldwide: a systematic review and meta-analysis. Health Qual Life Outcomes 2020 Nov 11;18(1):363. doi: 10.1186/s12955-020-01609-4

5. Wu T, Jia X, Shi H, Niu J, Yin X, Xie J et al. Prevalence of mental health problems during the COVID-19 pandemic: A systematic review and meta-analysis. J Affect Disord 2021 Feb;281(January):91-8

6. World Health Organization [WHO]. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva 1992

7. Spitzer RL, Kroenke K, Williams JW, Löwe B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med 2006;166(10):1092-7

8. Liebowitz MR. Social Phobia. In: Round Table Series - Royal Society of Medicine 1999:141-73

9. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. Published date: 26 January 2011 Last updated: 26 July 2019. https://www.nice.org.uk/guidance/cg113

10. Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Gdańsk 2015

11. Davidson JR et al. A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD). J Psychopharmacol 2010;24:3-26

12. Baldwin D et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta‐analysis. BMJ 2011;342:d1199

13. Clayton AH et al. Sex differences in clinical presentation and response in panic disorder: pooled data from sertraline treatment studies. Arch Womens Ment Health 2006;9:151-7

14. Martenyi F et al. Fluoxetine v. placebo in prevention of relapse in post‐traumatic stress disorder. Br J Psychiatry 2002;181:315-20

15. The Expert Consensus Panel for obsessive‐compulsive disorder. Treatment of obsessive‐compulsive disorder. J Clin Psychiatry 1997;58 Suppl 4:2-72

16. Delgado PL. Monoamine depletion studies: implications for antidepressant discontinuation syndrome. J Clin Psychiatry 2006; 67 Suppl 4:22-6

17. Tyrer P. Benzodiazepine dependence: a shadowy diagnosis. Biochem Soc Symp. 1993;59:107-19. PMID: 7910738

18. Baldwin D, Anderson IM, Nutt DJ et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology2014, vol. 28(5)403-39. DOI: 10.1177/0269881114525674